Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

11 Insider Trades To Keep An Eye On

Page 1 of 2

Hedge fund and insider trading are two types of sentiment that offer market-beating potential.

Insider buying activity has been shown to generate annual outperformance of about 7 percentage points, according to multiple empirical studies. With that being said, hedge fund data can be seen by following the link, and we’ll take you through a few of the most important insider buys of the past couple weeks below.

Repros Therapeutics Inc (NASDAQ:RPRX)

Repros Therapeutics

Repros Therapeutics Inc (NASDAQ:RPRX) CFO Katherine Anderson bought 1,000 shares of the reproductive health company at a price of $23.77 each. The move came amid safety and efficacy results for Androxal, a drug design to increase testosterone in men, which in essence, preserves fertility. Since Anderson’s move, shares of Repros have risen by 5% and if analysts’ expectations regarding Androxal are correct, the stock has further upside. With clinical development costs representing a major portion of Repros’ expenditures, the company is tied to the drug’s fate, so it’s clear which way one exec is betting.

KB Home

KB Home (NYSE:KBH), meanwhile, is in the middle of three insider purchases. Thomas Silk, SVP of Marketing and Communications at the company, bought 5,000 shares at $6.04 each, CEO Jeffrey Mezger snatched up 150,000 shares, and CFO Jeff Kaminski bought 15,000 shares. KB Home’s stock price performed fairly well in the first half of 2013, but a revenue miss in its latest quarter has sent shares down by about 5% in the past month. The company’s trio of bullish insiders makes the U.S.’s fifth-largest homebuilder worth watching.

Page 1 of 2
Loading...